SCHEDULE: David Bogart Discloses 8.1% Stake in Conexeu Sciences

David Bogart has filed a Schedule 13G, reporting beneficial ownership of 2,293,750 shares, representing 8.1% of Conexeu Sciences Inc.'s common stock.

Summary

• David Bogart has reported beneficial ownership of 2,293,750 shares of Conexeu Sciences Inc. common stock.
• This ownership stake represents 8.1% of the class of securities.
• The reported shares include directly held shares, shares held by a controlled entity (0865546 B.C. Ltd.), and shares issuable upon exercise of vested stock options and performance warrants.
• The filing excludes shares from unvested performance warrants that are contingent on a 510(k) application submission to the FDA.
• The calculation of the percentage ownership considers outstanding shares as of August 17, 2026, and includes shares from vested options and warrants deemed outstanding for this purpose.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the disclosure of significant beneficial ownership and the potential for future share increases through vested options and warrants, balanced by the fact that it's a routine Schedule 13G filing.

Positives

• Disclosure of a significant beneficial ownership stake (8.1%) by David Bogart.
• The reported ownership includes shares from vested options and warrants, indicating potential for increased future ownership.
• The filing is a routine Schedule 13G, suggesting no immediate adverse events or significant changes requiring a more detailed filing.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Conexeu Sciences Inc.
• A portion of potential shares (from unvested warrants) are contingent on regulatory approval (510(k) application), introducing uncertainty.

Risks

• The vesting of 250,000 performance warrants is contingent upon the submission of a 510(k) application to the U.S. Food and Drug Administration, which may not be approved.
• The calculation of ownership percentage is based on a specific date (August 17, 2026) and may change with subsequent share issuances or repurchases.

Future Outlook

The filing does not contain forward-looking statements or guidance. However, it notes that 750,000 shares are issuable upon exercise of vested performance warrants, and 250,000 shares are issuable upon exercise of unvested performance warrants contingent on a 510(k) application submission.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant beneficial ownership changes. This filing indicates a substantial personal investment by David Bogart in Conexeu Sciences Inc., which can be viewed positively by the market if Bogart is a key executive or strategic partner.

Stakeholder Impact

• Shareholders may view the increased disclosure of beneficial ownership by David Bogart positively, potentially signaling confidence in the company's prospects.
• Employees holding stock options and warrants may see this as a positive indicator of management's commitment and potential future value realization.

Next Steps

• The vesting of 250,000 performance warrants is contingent on the submission of a 510(k) application to the FDA.

Key Dates

Keywords

Conexeu Sciences, Schedule 13G, Beneficial Ownership, David Bogart, Common Stock, Stock Options, Performance Warrants, SEC Filing